1.26%
-4.37%
-15.96%
-31.41%
-40.72%
-35.30%
-45.61%
AI Spotlight on BIIB
Company Description
Biogen Inc.discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE.In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development.
The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc.Biogen Inc.was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 146.23 |
| Change Percentage | 1.26% |
| Open | 145.84 |
| Previous Close | 144.41 |
| Market Cap ( Millions) | 21308 |
| Volume | 1044096 |
| Year High | 249.33 |
| Year Low | 139.71 |
| M A 50 | 152.13 |
| M A 200 | 193.29 |
Financial Ratios
| FCF Yield | 8.30% |
| Dividend Yield | 0.00% |
| ROE | 10.38% |
| Debt / Equity | 40.66% |
| Net Debt / EBIDTA | 171.03% |
| Price To Book | 1.3 |
| Price Earnings Ratio | 13.19 |
| Price To FCF | 12.05 |
| Price To sales | 2.27 |
| EV / EBITDA | 9.07 |
News
- 11:46 - Europe to review safety data for Eisai-Biogen Alzheimer's drug
- 11:30 - Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
- Jan -27 - BIIB Secures FDA Nod for Monthly Maintenance Dosing of Alzheimer's Drug
- Jan -27 - Sage rejects Biogen's $469 million takeover offer
- Jan -26 - US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
- Jan -26 - FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
- Jan -26 - FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
- Jan -24 - FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
- Jan -23 - FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
- Jan -23 - Genetic Toxicology Testing Market Research 2024-2034: Increased R&D Activities, Strategic Collaborations, and a Focus on Personalized Therapy Boosts Growth
- Jan -21 - Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street Expert
- Jan -15 - Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
- Jan -14 - Biogen CEO sees no burning need for more acquisitions
- Jan -14 - FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
- Jan -13 - Biogen Offers to Buy Remaining Stake in Sage Therapeutics
- Jan -13 - Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
- Jan -13 - Sage takeout bid implies zero enterprise value, says Mizuho
- Jan -13 - Biogen bid for Sage does not change narrative, says BMO Capital
- Jan -13 - Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
- Jan -13 - Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Therapies
Expected Growth : 2.0 %
What the company do ?
Innovative Therapies from Biogen Inc. develops and commercializes novel treatments for autoimmune and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease.
Why we expect these perspectives ?
Biogen's Innovative Therapies segment growth is driven by increasing adoption of Spinraza for spinal muscular atrophy, strong sales of Tecfidera for multiple sclerosis, and growing demand for Ocrevus for relapsing multiple sclerosis. Additionally, the company's robust pipeline, including potential blockbusters like aducanumab for Alzheimer's disease, contributes to its growth momentum.
Biogen Inc. Products
| Product Range | What is it ? |
|---|---|
| TECFIDERA | An oral medication used to treat relapsing forms of multiple sclerosis (MS) |
| PLEGRIDY | A pegylated interferon beta-1a injection used to treat relapsing forms of MS |
| AVONEX | An interferon beta-1a injection used to treat relapsing forms of MS |
| RITUXAN | A monoclonal antibody used to treat rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia |
| SPINRAZA | An antisense oligonucleotide injection used to treat spinal muscular atrophy (SMA) in pediatric and adult patients |
| FUMADERM | A dimethyl fumarate oral medication used to treat moderate to severe plaque psoriasis |
Biogen Inc.'s Porter Forces
Threat Of Substitutes
Biogen Inc. faces moderate threat from substitutes due to the presence of alternative treatments and therapies for multiple sclerosis and other diseases.
Bargaining Power Of Customers
Biogen Inc. has a diverse customer base, and individual customers do not have significant bargaining power due to the company's strong brand presence and limited availability of alternative treatments.
Bargaining Power Of Suppliers
Biogen Inc. has a diversified supplier base, and no single supplier has significant bargaining power due to the company's large scale of operations and strong relationships with suppliers.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with Biogen Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with several established players competing for market share, and Biogen Inc. faces intense rivalry from companies such as Teva Pharmaceutical Industries, Novartis, and Roche Holding.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 33.15% |
| Debt Cost | 3.95% |
| Equity Weight | 66.85% |
| Equity Cost | 3.91% |
| WACC | 3.92% |
| Leverage | 49.58% |
Biogen Inc. : Quality Control
Biogen Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LLY | Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, … |
| PFE | Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin … |
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
Pfizer
A-Score
1-Year Total Return ->
🥉
Gilead Sciences
A-Score
1-Year Total Return ->
4
Merck
A-Score
1-Year Total Return ->
5
Lilly
A-Score
1-Year Total Return ->
6
